Q1 2022 EPS Estimates for Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Reduced by Jefferies Financial Group

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Rating) – Analysts at Jefferies Financial Group reduced their Q1 2022 earnings estimates for shares of Tarsus Pharmaceuticals in a research note issued to investors on Tuesday, May 3rd. Jefferies Financial Group analyst F. Pinal now forecasts that the company will earn ($1.45) per share for the quarter, down from their prior estimate of ($1.44). Jefferies Financial Group also issued estimates for Tarsus Pharmaceuticals’ Q2 2022 earnings at ($1.38) EPS, Q3 2022 earnings at ($0.99) EPS, Q4 2022 earnings at ($1.05) EPS, FY2022 earnings at ($4.81) EPS, FY2023 earnings at ($4.90) EPS, FY2024 earnings at ($3.72) EPS, FY2025 earnings at $0.20 EPS and FY2026 earnings at $3.88 EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS – Get Rating) last posted its quarterly earnings results on Monday, March 14th. The company reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.05. The company had revenue of $0.34 million for the quarter, compared to the consensus estimate of $7.11 million. Tarsus Pharmaceuticals had a negative return on equity of 7.66% and a negative net margin of 24.25%.

Other analysts have also issued reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Tarsus Pharmaceuticals in a research note on Tuesday. Oppenheimer upped their price objective on Tarsus Pharmaceuticals from $55.00 to $66.00 in a research report on Monday. Finally, Zacks Investment Research raised shares of Tarsus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, February 24th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $48.00.

Tarsus Pharmaceuticals stock opened at $12.05 on Friday. Tarsus Pharmaceuticals has a one year low of $11.76 and a one year high of $39.08. The business’s fifty day moving average is $17.81 and its 200 day moving average is $21.17.

In related news, major shareholder Vivo Capital Ix, Llc sold 19,738 shares of Tarsus Pharmaceuticals stock in a transaction on Wednesday, May 4th. The shares were sold at an average price of $12.67, for a total transaction of $250,080.46. Following the transaction, the insider now owns 2,474,375 shares in the company, valued at approximately $31,350,331.25. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 33.08% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of TARS. Morgan Stanley bought a new stake in Tarsus Pharmaceuticals in the 2nd quarter worth approximately $241,000. SG Americas Securities LLC raised its position in Tarsus Pharmaceuticals by 101.3% during the third quarter. SG Americas Securities LLC now owns 46,253 shares of the company’s stock valued at $997,000 after purchasing an additional 23,276 shares during the period. BlackRock Inc. lifted its stake in shares of Tarsus Pharmaceuticals by 0.7% in the 3rd quarter. BlackRock Inc. now owns 441,620 shares of the company’s stock valued at $9,519,000 after purchasing an additional 3,264 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Tarsus Pharmaceuticals by 13.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 24,523 shares of the company’s stock worth $529,000 after purchasing an additional 2,950 shares during the period. Finally, Allspring Global Investments Holdings LLC bought a new position in Tarsus Pharmaceuticals during the fourth quarter valued at $289,000. 70.00% of the stock is currently owned by institutional investors.

Tarsus Pharmaceuticals Company Profile (Get Rating)

Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

Read More